Bénard J |
[From metastatic osteolysis a painful message: beginning to understand with osteoprotegerin? |
2000 |
Bull Cancer |
pmid:11184451
|
Yamashita T et al. |
Retardation in bone resorption after bone marrow ablation in klotho mutant mice. |
2000 |
Endocrinology |
pmid:10614667
|
Hofbauer LC et al. |
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. |
2000 |
J. Bone Miner. Res. |
pmid:10646108
|
Kanzawa M et al. |
Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. |
2000 |
Eur. J. Endocrinol. |
pmid:10822231
|
Mukohyama H et al. |
The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10777696
|
Atkins GJ et al. |
Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. |
2000 |
J. Bone Miner. Res. |
pmid:10780856
|
Thompson SW and Tonge D |
Bone cancer gain without the pain. |
2000 |
Nat. Med. |
pmid:10802700
|
Honore P et al. |
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. |
2000 |
Nat. Med. |
pmid:10802707
|
Onyia JE et al. |
In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. |
2000 |
J. Bone Miner. Res. |
pmid:10804015
|
Bateman TA et al. |
Osteoprotegerin mitigates tail suspension-induced osteopenia. |
2000 |
Bone |
pmid:10773583
|
Malyankar UM et al. |
Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. |
2000 |
J. Biol. Chem. |
pmid:10811631
|
Thirunavukkarasu K et al. |
The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. |
2000 |
J. Biol. Chem. |
pmid:10833509
|
Aubin JE and Bonnelye E |
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. |
2000 |
Medscape Womens Health |
pmid:10792853
|
Fata JE et al. |
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. |
2000 |
Cell |
pmid:11051546
|
Miyamoto N et al. |
Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. |
2000 |
J. Orthop. Res. |
pmid:11052502
|
Kinpara K et al. |
Osteoclast differentiation factor in human osteosarcoma cell line. |
2000 |
J Immunoassay |
pmid:11071251
|
Kong YY et al. |
Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
2000 |
Immunol. Today |
pmid:11071528
|
Kobayashi Y et al. |
Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. |
2000 |
J. Bone Miner. Res. |
pmid:11028444
|
Kaneda T et al. |
Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. |
2000 |
J. Immunol. |
pmid:11035059
|
Miyamoto T et al. |
An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. |
2000 |
Blood |
pmid:11110710
|
|
Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. |
2000 |
Bone |
pmid:11113385
|
Lee ZH et al. |
Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. |
2000 |
Mol. Pharmacol. |
pmid:11093794
|
Kong YY and Penninger JM |
Molecular control of bone remodeling and osteoporosis. |
2000 |
Exp. Gerontol. |
pmid:11121682
|
Shalhoub V et al. |
Characterization of osteoclast precursors in human blood. |
2000 |
Br. J. Haematol. |
pmid:11122091
|
|
Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. |
2000 |
J. Bone Miner. Res. |
pmid:11127193
|
Sakuma Y et al. |
Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. |
2000 |
Infect. Immun. |
pmid:11083800
|
Riggs BL |
The mechanisms of estrogen regulation of bone resorption. |
2000 |
J. Clin. Invest. |
pmid:11086020
|
Udagawa N et al. |
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. |
2000 |
Endocrinology |
pmid:10965921
|
Yasuda H |
[A new paradigm of osteoclast biology: discovery of OCIF and ODF]. |
2000 |
Seikagaku |
pmid:10967683
|
Teitelbaum SL |
Bone resorption by osteoclasts. |
2000 |
Science |
pmid:10968780
|
Lacey DL et al. |
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. |
2000 |
Am. J. Pathol. |
pmid:10934148
|
Quinn JM et al. |
Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. |
2000 |
J. Bone Miner. Res. |
pmid:10934644
|
Min H et al. |
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. |
2000 |
J. Exp. Med. |
pmid:10952716
|
Shiba H et al. |
Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. |
2000 |
Mech. Ageing Dev. |
pmid:10958924
|
López FJ |
New approaches to the treatment of osteoporosis. |
2000 |
Curr Opin Chem Biol |
pmid:10959765
|
Nakashima T et al. |
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10973797
|
Itoh K et al. |
Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. |
2000 |
J. Bone Miner. Res. |
pmid:10976996
|
Schinke T and Karsenty G |
Vascular calcification--a passive process in need of inhibitors. |
2000 |
Nephrol. Dial. Transplant. |
pmid:10978374
|
Lorenzo J |
Interactions between immune and bone cells: new insights with many remaining questions. |
2000 |
J. Clin. Invest. |
pmid:10995785
|
Teng YT et al. |
Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. |
2000 |
J. Clin. Invest. |
pmid:10995794
|
Børset M et al. |
Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. |
2000 |
Blood |
pmid:11001907
|
Hofbauer LC and Heufelder AE |
Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. |
2000 |
J. Clin. Endocrinol. Metab. |
pmid:10902778
|
Rani CS and MacDougall M |
Dental cells express factors that regulate bone resorption. |
2000 |
Mol. Cell Biol. Res. Commun. |
pmid:10860862
|
Tsurukai T et al. |
Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. |
2000 |
J. Bone Miner. Metab. |
pmid:10874596
|
Günther T and Schinke T |
Mouse genetics have uncovered new paradigms in bone biology. |
2000 |
Trends Endocrinol. Metab. |
pmid:10856921
|
Huang L et al. |
Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. |
2000 |
Am. J. Pathol. |
pmid:10702390
|
Capparelli C et al. |
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. |
2000 |
Cancer Res. |
pmid:10706080
|
Makhluf HA et al. |
Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10679262
|
Merewether LA et al. |
Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. |
2000 |
Arch. Biochem. Biophys. |
pmid:10683254
|
Takayanagi H et al. |
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. |
2000 |
Arthritis Rheum. |
pmid:10693864
|
Itonaga I et al. |
Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. |
2000 |
Ann. Rheum. Dis. |
pmid:10627423
|
Chikatsu N et al. |
Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. |
2000 |
Biochem. Biophys. Res. Commun. |
pmid:10631114
|
Takami M et al. |
Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. |
2000 |
Endocrinology |
pmid:11108286
|
Gori F et al. |
The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. |
2000 |
Endocrinology |
pmid:11108292
|
Clohisy DR et al. |
Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. |
2000 |
J. Orthop. Res. |
pmid:11192258
|
Aubin JE and Bonnelye E |
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. |
2000 |
Osteoporos Int |
pmid:11193242
|
Wise GE et al. |
Osteoprotegerin and osteoclast differentiation factor in tooth eruption. |
2000 |
J. Dent. Res. |
pmid:11201042
|
Kotake S et al. |
[Molecular mechanism of bone metabolism]. |
2000 |
Nippon Naika Gakkai Zasshi |
pmid:11215116
|
Kanematsu M et al. |
[Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. |
2000 |
Biol. Sci. Space |
pmid:12561872
|
Saika M et al. |
17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. |
2001 |
Endocrinology |
pmid:11356664
|
Mackie PS et al. |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. |
2001 |
Br. J. Cancer |
pmid:11286476
|
Hofbauer LC et al. |
Osteoprotegerin, RANK, and RANK ligand: the good, the bad, and the ugly in rheumatoid arthritis. |
2001 |
J. Rheumatol. |
pmid:11327234
|
Hofbauer LC and Heufelder AE |
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. |
2001 |
Arthritis Rheum. |
pmid:11229454
|
Goltzman D |
Osteolysis and cancer. |
2001 |
J. Clin. Invest. |
pmid:11375409
|
Zhang J et al. |
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. |
2001 |
J. Clin. Invest. |
pmid:11375413
|
Kostenuik PJ and Shalhoub V |
Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. |
2001 |
Curr. Pharm. Des. |
pmid:11375772
|
Sasaki N et al. |
Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. |
2001 |
Nephrol. Dial. Transplant. |
pmid:11239019
|
Takeuchi T et al. |
Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. |
2001 |
Biochem. Pharmacol. |
pmid:11239501
|
Mori K et al. |
Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. |
2001 |
Cell. Immunol. |
pmid:11243701
|
Hofbauer LC et al. |
Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11162519
|
Brändström H et al. |
Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. |
2001 |
Biochem. Biophys. Res. Commun. |
pmid:11162596
|
Wuyts W et al. |
Evaluation of the role of RANK and OPG genes in Paget's disease of bone. |
2001 |
Bone |
pmid:11165949
|
Michigami T et al. |
Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. |
2001 |
Cancer Res. |
pmid:11245477
|
Wada N et al. |
Periodontal ligament cells secrete the factor that inhibits osteoclastic differentiation and function: the factor is osteoprotegerin/osteoclastogenesis inhibitory factor. |
2001 |
J. Periodont. Res. |
pmid:11246705
|
Jung K et al. |
Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. |
2001 |
Clin. Chem. |
pmid:11673385
|
Lean JM et al. |
FLT3 ligand can substitute for macrophage colony-stimulating factor in support of osteoclast differentiation and function. |
2001 |
Blood |
pmid:11675341
|
Fiumara P et al. |
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. |
2001 |
Blood |
pmid:11675352
|
Satoh K et al. |
Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. |
2001 |
Pancreas |
pmid:11590320
|
Pearse RN et al. |
Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11562486
|
Kostenuik PJ et al. |
OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. |
2001 |
Endocrinology |
pmid:11564687
|
Marco-Mingot M et al. |
Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. |
2001 |
Clin. Genet. |
pmid:11531977
|
Raffai RL et al. |
Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. |
2001 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:11553788
|
Hocking LJ et al. |
Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. |
2001 |
Am. J. Hum. Genet. |
pmid:11555792
|
Hofbauer LC et al. |
Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. |
2001 |
Cancer |
pmid:11505389
|
Hofbauer LC and Heufelder AE |
Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. |
2001 |
J. Mol. Med. |
pmid:11485016
|
Furuya D et al. |
Immuno-PCR assay for homodimeric osteoprotegerin. |
2001 |
Clin. Chem. |
pmid:11468243
|
Seck T et al. |
Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. |
2001 |
Eur. J. Endocrinol. |
pmid:11454517
|
Burguera B et al. |
Leptin reduces ovariectomy-induced bone loss in rats. |
2001 |
Endocrinology |
pmid:11459801
|
Yamagishi T et al. |
Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. |
2001 |
Endocrinology |
pmid:11459812
|
Ma YL et al. |
Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. |
2001 |
Endocrinology |
pmid:11517184
|
Halladay DL et al. |
Identification of signal transduction pathways and promoter sequences that mediate parathyroid hormone 1-38 inhibition of osteoprotegerin gene expression. |
2001 |
J. Cell. Biochem. |
pmid:11746511
|
Cao Y et al. |
IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. |
2001 |
Cell |
pmid:11747812
|
Chung H et al. |
Deflazacort increases osteoclast formation in mouse bone marrow culture and the ratio of RANKL/OPG mRNA expression in marrow stromal cells. |
2001 |
J. Korean Med. Sci. |
pmid:11748360
|
Komuro H et al. |
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. |
2001 |
Arthritis Rheum. |
pmid:11762937
|
Fukagawa M et al. |
[PTH and bone metabolism in chronic dialysis patients]. |
2001 |
Rinsho Byori |
pmid:11307321
|
Horowitz MC et al. |
Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. |
2001 |
Cytokine Growth Factor Rev. |
pmid:11312114
|
Lin DL et al. |
Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. |
2001 |
Prostate |
pmid:11351351
|
Sparks AB et al. |
Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. |
2001 |
Calcif. Tissue Int. |
pmid:11351498
|
Disthabanchong S and González EA |
Regulation of bone cell development and function: implication for renal osteodystrophy. |
2001 |
J. Investig. Med. |
pmid:11352181
|
Kotake S et al. |
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. |
2001 |
Arthritis Rheum. |
pmid:11352231
|